Small Cell Carcinoma of Urinary Bladder: Analysis from a Tertiary Cancer Care Center of India

Abstract

Context: Small cell cancer of the urinary bladder. Aims: Small cell carcinoma of the bladder is a rare histological subtype, which is particularly aggressive and global literature available describing this entity is sparse. This review of our database was to evaluate clinicopathological and survival outcomes of these patients. Subjects and Methods: The present study was a retrospective analysis of patients with small cell bladder cancer for past 6 years at Rajiv Gandhi Cancer Institute and Research Center, New Delhi. Results:: Most of the patients in our study presented with limited stage disease. The overall survival and disease-free survival (DFS) was 49% and 51.07% at 2 years, respectively. Preoperative chemotherapy with surgical resection has shown significant survival and DFS benefit. Stage at presentation also affected the survival and DFS though it did not reach statistical significance. Conclusions: Small cell bladder cancer is a rare disease with dismal prognosis. Multimodality treatment with neoadjuvant chemotherapy should be the preferred treatment for limited stage disease.

Keywords

India - neuroendocrine carcinoma - small cell bladder carcinoma

Publication History

Article published online:
17 June 2021

• References

• 1 Thota S, Kistangari G, Daw H, Spiro T. A clinical review of small-cell carcinoma of the urinary bladder. Clin Genitourin Cancer 2013;11:73-7 2013; 11: 73-7
• 2 Koay EJ, Teh BS, Paulino AC, Butler EB. A surveillance, epidemiology, and end results analysis of small cell carcinoma of the bladder: Epidemiology, prognostic variables, and treatment trends. Cancer 2011; 117: 5325-33
• 3 Moretto P, Wood L, Emmenegger U, Blais N, Mukherjee SD, Winquist E. et al. Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Can Urol Assoc J 2013; 7: E44-56
• 4 Chhabra S, Hegde P, Singhal P. Primary small cell carcinoma of the urinary bladder – Mini-review of the literature. Asian Pac J Cancer Prev 2012;13:3549-53 2012; 13: 3549-53
• 5 Kouba E, Cheng L. Neuroendocrine tumors of the urinary bladder according to the 2016 World Health Organization classification: Molecular and clinical characteristics. Endocr Pathol 2016; 27: 188-99
• 6 Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H. et al. Small cell carcinoma of the urinary bladder: A clinicopathologic analysis of 64 patients. Cancer 2004; 101: 957-62
• 7 Pasquier D, Barney B, Sundar S, Poortmans P, Villa S, Nasrallah H. et al. Small cell carcinoma of the urinary bladder: A Retrospective, multicenter rare cancer network study of 107 patients. Int J Radiat Oncol Biol Phys 2015; 92: 904-10
• 8 Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder The mayo clinic experience. Cancer 2005; 103: 1172-8
• 9 Bex A, Sonke GS, Pos FJ, Brandsma D, Kerst JM, Horenblas S. et al. Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The netherlands cancer institute experience and literature review. Ann Oncol 2010; 21: 2240-5
• 10 Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE. et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: Results from a retrospective study at the MD Anderson cancer center. Eur Urol 2013; 64: 307-13
• 11 Available from: http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. [Last accessed on 2017 Jan 16].
• 12 Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF. et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 2009; 27: 2592-7
• 13 Nabi G, Singh I, Ansari MS, Sharma MC, Dogra PN. Primary small cell neuroendocrine carcinoma of urinary bladder: An uncommon entity to be recognized. Int Urol Nephrol 2001; 33: 637-40